UK-US biotech investor Epidarex raises $145M for fourth fundnews2026-01-27T07:00:57+00:00January 27th, 2026|Endpoints News|
F2G CEO outlines biotech’s FDA resubmission plans, funding and expansionnews2026-01-23T16:38:10+00:00January 23rd, 2026|Endpoints News|
BioMarin vets spearhead new biotech with $82M for rare disease drugsnews2026-01-22T12:00:19+00:00January 22nd, 2026|Endpoints News|
Think Bioscience gets $55M to unearth new drug pocketsnews2026-01-21T12:00:50+00:00January 21st, 2026|Endpoints News|
Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drugnews2026-01-20T06:30:30+00:00January 20th, 2026|Endpoints News|
Agomab and SpyGlass file for IPOs as investor enthusiasm builds after JPMnews2026-01-16T22:05:40+00:00January 16th, 2026|Endpoints News|
Health tech funding rounds get bigger when Andreessen Horowitz and General Catalyst joinnews2026-01-14T18:43:51+00:00January 14th, 2026|Endpoints News|
Caldera Therapeutics erupts with $112.5M and a China-originated IBD bispecificnews2026-01-14T12:00:39+00:00January 14th, 2026|Endpoints News|
Marea takes drug for acromegaly to Phase 2news2026-01-13T13:00:12+00:00January 13th, 2026|Endpoints News|
Treg biotech Sonoma sheds staff after getting new CEOnews2026-01-13T09:13:48+00:00January 13th, 2026|Endpoints News|
